Clinical studySide effects of systemic cyclosporine in patients not undergoing transplantation
References (19)
- et al.
Treatment of intraocular inflammatory disease with cyclosporin A
Lancet
(1983) - et al.
Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents
Am J Ophthalmol
(1983) - et al.
Hyperbilirubinaemia and cyclosporin A levels in renal transplant patients
Lancet
(1981) - et al.
Two cases of benign lumps after treatment with cyclosporin A
Lancet
(1980) - et al.
Cyclosporine: speculation about its mechanism of action
Transplant Proc
(1983) - et al.
Cyclosporin A and steroids for liver and heart transplantation
- et al.
Nephrotoxicity in marrow graft recipients treated with cyclosporine
Transplant Proc
(1983) - et al.
Nephrotoxicity in renal recipients
Transplant Proc
(1983) - et al.
Renal failure (RF) in heart transplant patients receiving cyclosporine
Transplant Proc
(1983)
Cited by (264)
Cis-trans isomerization in cyclosporin C dissolved in acetonitrile
2023, Biochemical and Biophysical Research CommunicationsOcular delivery of cyclosporine A using dissolvable microneedle contact lens
2022, Journal of Drug Delivery Science and TechnologyAre Adverse Events Induced by the Acute Administration of Calcineurin Inhibitor Cyclosporine A Behaviorally Conditioned in Healthy Male Volunteers?
2018, Clinical TherapeuticsCitation Excerpt :Healthy male volunteers aged ≥18 years were recruited by public advertisements in the surrounding community. In addition to information on possible serious adverse events while on long-term CsA treatment, participants were informed about 4 potential, subjectively perceivable, and highly frequent CsA-related adverse events that can occur with short-term CsA administration according to Ellis et al,31 Gupta et al,32 Palestine et al,33 and Wendt et al34 (ie, heat sensation in the hands and head, tingling sensation in the hands, fatigue/faster exhaustion, and nausea/discomfort in the intestine and stomach). All participants underwent in-depth physical and psychological assessments, including self-reported questionnaires and an interview about their medical history.
Drug-associated hidradenitis suppurativa: A systematic review of case reports
2018, Journal of the American Academy of DermatologyCyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts
2017, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :Initially, CsA was administered orally for the treatment of ophthalmic diseases. Although CsA was able to reach therapeutic levels in different ocular tissues [9], the non-ocular administration led to occurrence of systemic adverse events such as nephrotoxicity, hypertension, anemia, paresthesia and hyperesthesia [10]. Therefore, local (ocular) administration of CsA-loaded products became the preferred method of delivery for treatment of ophthalmic pathologies.
Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier
2015, Toxicology in VitroCitation Excerpt :As PK evaluation is necessary to describe the systemic exposure and its relationship to observed (adverse) effects, PK data enhance the understanding of mechanisms of action and/or toxicity induced by xenobiotics and moreover help to assess the risk and safety in humans (ICH S3A Guideline; OECD Test Guideline No. 417). The cyclic peptide cyclosporine A (CsA), which is a widely used immunosuppressive compound, was chosen as a cross-organ test compound in the “Predict-IV” project as it has been shown to induce hepatotoxicity (Atkinson et al., 1983; Klintmalm et al., 1981), nephrotoxicity (Bennett and Pulliam, 1983; Klintmalm et al., 1985; Palestine et al., 1984) and also neurotoxicity (Calne et al., 1979; Gijtenbeek et al., 1999). As the therapeutic index of CsA is narrow, therapy requires drug monitoring to avoid toxicity.
- 1
From the Clinical Ophthalmic Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, Maryland.